Life Sciences – IMAA – Institute for Mergers, Acquisitions, and Alliances

Publications

Deal Tectonics: At The Fault Line Of Growth Goals And Competitive Pressures

by Ernst & Young
As the specialty pharmaceutical sector sees its ability to pursue large acquisitions evaporate, long-promised organic growth from big pharma new drug launches has finally arrived. But a renewed focus on value-based pricing, staunch competition across key therapeutic battlefields and consolidating payer clout may weaken the industry’s ability to reach revenue targets for both new and legacy therapeutics. […] Read more

December 9, 2015

Publications

Dealing With Uncertainty: Strategies For Overcoming Compliance Risk And Regulatory Challenges In Cross-Border M&A

by Baker & McKenzie
When you look at the numbers, there’s no question why global pharmaceutical companies have set their sights on emerging markets for future growth. From 2012 to 2017, global pharmaceutical sales are expected to rise 13% in the “pharmerging markets,” compared to 2% for the top mature markets, according to the IMS Institute for Healthcare Informatics. […] Read more

March 5, 2015

2016 Asian Trailblazers Study: Masters Of Multitasking And Transformation

Publications

Firepower Fireworks: Focus, Scale And Growth Drive Explosive M&A

by Ernst & Young
Record biopharma M&A exceeded US$200 billion in 2014, well over twice the average annual deal volume seen in the last decade, as companies used deal making to satisfy the strategic imperatives of increasing focus, scale and/or growth. A convergence of forces fueled the fireworks, including rising equity valuations, historically low interest rates and prodigious firepower. […] Read more

January 1, 2015

Publications

M&A Trends In Life Sciences And Health Care: Growth At The Global Intersection Of Change

by Deloitte
Anyone witnessing the feverish deal-making that has swept through the global life sciences and health care industry recently might well conclude that mergers-and-acquisitions (M&A) activity has become the dominant force shaping the industry. According to Thomson Reuters, the global year-to-date value of deals in the life sciences sector alone was $600bn for July 2014, compared with $200bn for the same period last year. […] Read more

September 16, 2014

Tag: Life Sciences

Deal Tectonics: At The Fault Line Of Growth Goals And Competitive Pressures

Dealing With Uncertainty: Strategies For Overcoming Compliance Risk And Regulatory Challenges In Cross-Border M&A

Firepower Fireworks: Focus, Scale And Growth Drive Explosive M&A

M&A Trends In Life Sciences And Health Care: Growth At The Global Intersection Of Change

Are you sure you
want to log out?

Tag: Life Sciences

Deal Tectonics: At The Fault Line Of Growth Goals And Competitive Pressures

Dealing With Uncertainty: Strategies For Overcoming Compliance Risk And Regulatory Challenges In Cross-Border M&A

Firepower Fireworks: Focus, Scale And Growth Drive Explosive M&A

M&A Trends In Life Sciences And Health Care: Growth At The Global Intersection Of Change

Are you sure youwant to log out?

Are you sure you
want to log out?